DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial

P. Forde; H. Kindler; M. Zauderer; Z. Sun; S. Ramalingam; V. Anagnostou; J. R. Brahmer; A. K. Nowak; P. S. Kok; C. Brown; S. Yip; A. Cook; W. J. Lesterhuis; B. G. M. Hughes; N. Pavlakis; M. R. Stockler; K. J. O'Byrne

DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial

P. Forde, H. Kindler, M. Zauderer, Z. Sun, S. Ramalingam, V. Anagnostou, J. R. Brahmer, A. K. Nowak, P. S. Kok, C. Brown, S. Yip, A. Cook, W. J. Lesterhuis, B. G. M. Hughes, N. Pavlakis, M. R. Stockler, K. J. O'Byrne

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	E9-E10
Number of pages	2
Journal	International Journal of Radiation Oncology Biology Physics
Volume	112
Issue number	2
Publication status	Published - 1 Feb 2022

Cite this

Forde, P., Kindler, H., Zauderer, M., Sun, Z., Ramalingam, S., Anagnostou, V., Brahmer, J. R., Nowak, A. K., Kok, P. S., Brown, C., Yip, S., Cook, A., Lesterhuis, W. J., Hughes, B. G. M., Pavlakis, N., Stockler, M. R., & O'Byrne, K. J. (2022). DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial. International Journal of Radiation Oncology Biology Physics, 112(2), E9-E10.

@article{6ad936e137094bfb913a9df606b4ba3c,

title = "DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial",

author = "P. Forde and H. Kindler and M. Zauderer and Z. Sun and S. Ramalingam and V. Anagnostou and Brahmer, {J. R.} and Nowak, {A. K.} and Kok, {P. S.} and C. Brown and S. Yip and A. Cook and Lesterhuis, {W. J.} and Hughes, {B. G. M.} and N. Pavlakis and Stockler, {M. R.} and O'Byrne, {K. J.}",

year = "2022",

month = feb,

day = "1",

language = "English",

volume = "112",

pages = "E9--E10",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Academic Press",

number = "2",

}

Forde, P, Kindler, H, Zauderer, M, Sun, Z, Ramalingam, S, Anagnostou, V, Brahmer, JR, Nowak, AK, Kok, PS, Brown, C, Yip, S, Cook, A, Lesterhuis, WJ, Hughes, BGM, Pavlakis, N, Stockler, MR & O'Byrne, KJ 2022, 'DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial', International Journal of Radiation Oncology Biology Physics, vol. 112, no. 2, pp. E9-E10.

TY - JOUR

T1 - DREAM3R

T2 - DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial

AU - Forde, P.

AU - Kindler, H.

AU - Zauderer, M.

AU - Sun, Z.

AU - Ramalingam, S.

AU - Anagnostou, V.

AU - Brahmer, J. R.

AU - Nowak, A. K.

AU - Kok, P. S.

AU - Brown, C.

AU - Yip, S.

AU - Cook, A.

AU - Lesterhuis, W. J.

AU - Hughes, B. G. M.

AU - Pavlakis, N.

AU - Stockler, M. R.

AU - O'Byrne, K. J.

PY - 2022/2/1

Y1 - 2022/2/1

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000740708800015

M3 - Abstract/Meeting Abstract

SN - 0360-3016

VL - 112

SP - E9-E10

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 2

ER -

DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial

Other files and links

Cite this